Findings support model in which accelerated biological aging of mammary epithelia may underpin breast cancer susceptibility ...

An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...

Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...

TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...

Artificial intelligence (AI) could help physicians determine if survivors of childhood cancer need extra support - and the more information included in AI prompting, the better its performance. This ...

Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...

New cfDNA test enables multicancer detection with high accuracy, offering a cost effective approach for early diagnosis and ...

TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...

A recent study published in Cell Reports Medicine has identified distinct microbial signatures within the oral cavity and gut ...